(Press-News.org) The COVID-19 pandemic has enabled researchers to show that a long course of radiotherapy given before surgery may be a better treatment for avoiding surgery, preserving the rectum and anus, and preventing regrowth of the primary tumour than a short course of radiotherapy for patients with rectal cancer – a type of bowel cancer. However, the overall survival and survival free of recurrence of the disease remained the same for both treatments.
These findings are from a new study published in the leading cancer journal Annals of Oncology [1] today (Thursday), and the researchers say that they “fill a crucial knowledge gap” about which treatment is better for preserving these important organs. This can make a real difference to patients’ quality of life because, if part of the bowel or anus needs to be removed during surgery to eradicate the tumour, some patients are fitted with a stoma or colostomy (a hole in the abdominal wall that connects to the bowel) through which faeces pass into a disposable bag worn over the hole.
Dr Paul Romesser, director of colorectal anal cancer radiation oncology at Memorial Sloan Kettering Cancer Center, New York, USA, who co-led the study with Dr J. Joshua Smith, associate attending surgeon at MSK, said: “The COVID pandemic, particularly intense in New York, forced us to re-evaluate resource allocation and treatment options to protect patients and staff by shortening the time they were exposed to each other. This led us to mandate that all rectal cancer patients be treated with short-course radiotherapy, SCRT, without exception, based on evidence from multiple prospective trials showing similar outcomes.
“The crucial knowledge gaps were whether organ preservation is safe after SCRT and which radiation treatment is best if organ preservation is the goal. Until now, there were no studies comparing SCRT and long course of chemoradiotherapy, LCCRT, in terms of organ preservation and local regrowth rates. Our study is the first to address both, finding that organ preservation by avoiding surgery after neoadjuvant SCRT is safe and may be preferred for some patients due to the convenience of treatment. However, the tumour regrowth rate was higher, necessitating close monitoring. If time and convenience aren’t factors, LCCRT appears to offer more durable organ preservation.”
The COVID pandemic enabled the researchers to create a “natural” experiment to compare the two forms of treatment, rather than conducting a randomised controlled trial. The study included 323 patients with locally advanced rectal cancer (cancer that had grown outside the rectum but had not yet spread to other parts of the body) who were treated with either SCRT or LCCRT as a neoadjuvant therapy to shrink the tumour before surgery between January 2020 and January 2021. If they were treated between March and June 2020 and between November 2020 and January 2021, they received SCRT (76 patients). Outside these periods, patients were treated with LCCRT (247 patients). Both groups of patients also received chemotherapy as well.
Patients who achieved a clinical complete response, meaning the tumour was no longer detectable, were offered “watch and wait” management instead of surgery, involving close monitoring during follow-up. Those who achieved a near complete response were re-evaluated in 6-12 weeks to allow additional time for their tumours to respond and if they then had a complete response, they were also offered “watch and wait” management. Patients with residual tumour, and those who declined “watch and wait”, underwent surgery to remove the rectum, the fatty tissue, lymph nodes and blood vessels around it to reduce the chances of the tumour coming back (this procedure is called a total mesorectal excision).
After an average (median) of 31 months, 44.5% of patients receiving LCCRT and 43.4% of patients receiving SCRT had a complete response. After two years, organ preservation was achieved in 40% of LCCRT and 31% of SCRT patients. In patients managed with “watch and wait”, LCRT resulted in higher organ preservation at two years (89% versus 70% in SCRT patients) and lower local regrowth (19% versus 36% respectively).
Recurrences of cancer in other parts of the body, disease free survival and overall survival were similar in “watch and wait” patients treated with LCCRT or SCRT: 10% versus 6.1%, 90% versus 90%, and 99% versus 100%, respectively.
Dr Smith said: “Our study also included information on patient-reported outcomes, which highlighted that patients who achieved organ preservation had good bowel function after both LCCRT and SCRT. The lack of differences in distant cancer recurrences, disease-free survival, and overall survival rates between the two groups is reassuring. It highlights the safety of integrating a ‘watch-and-wait approach’ into a neoadjuvant treatment strategy and the ability to treat patients successfully if local regrowth occurs. Most local regrowths can be detected with flexible endoscopies and occur in the first two years after completion of all treatment, underscoring the importance of close surveillance during “watch and wait.
“Despite similar clinical complete response rates, we observed more local regrowth after SCRT than LCCRT. This suggests that SCRT may be less durable than LCCRT. If the goal is lifelong organ preservation, LCCRT seems to be the preferred treatment option given our findings of more durable response with LCCRT.
“Given the rising incidence of rectal cancer in young adults it is critical to think about personalising treatments. There are times where patients with a clinical complete response undergo life-changing surgery only to find that no cancer was found in the surgical specimen. Patients and providers alike should be questioning the utility of surgery in settings such as this. The goal should be personalised treatment to maintain cure rates but avoid over-treatment.”
Dr Romesser said: “It’s important to stress that both treatments remain good options for patients, especially as overall survival is the same. There are situations where LCCRT is just not feasible and presents a burden to the patient and their family due to the frequent visits to hospital over a long period of time to receive the radiation therapy. In these circumstances, our data provide the support that organ preservation after SCRT is safe and feasible. They also help healthcare providers to understand patients treated with SCRT have a higher risk of local regrowth within the first two years. While organ preservation can be achieved after both SCRT and LCCRT, if the goal is an optimised approach, I’d recommend LCCRT followed by consolidative chemotherapy before surgery.”
The researchers will continue to monitor the patients to see how they do over a longer term of five to seven years.
“Our ultimate goal is personalised therapy based on the patient, the patient’s tumour genetics, and the goals of treatment. We are working to develop biomarkers that can predict response to LCCRT and SCRT. It is likely that some patients will do better or just as well with SCRT, whereas others need LCCRT. Instead of a cookie cutter approach our research is focused on optimising treatment for an individual patient and tumour,” concluded Dr Romesser.
Darth Ann Clurman, aged 48, a teacher who lives near Sacramento, California, USA, was told by general practitioners that she was too young to have bowel cancer.
“I was diagnosed in August of 2022 after having my symptoms dismissed with ‘you're too young’ and ‘you had two natural childbirths, it's probably haemorrhoids’ by three GPs who talked to me virtually. I was 46 when I was diagnosed with a 3-4 cm, mid-low, flat rectal tumour,” she said.
An MRI scan showed the tumour was advanced, having spread into the pelvic floor muscle but with no cancer in the lymph nodes (T4N0). At Kaiser Permanente’s Roseville and Rancho Cordova hospitals, she was treated with long-course chemoradiotherapy (LCCRT), which eradicated all signs of the cancer, so she was able to avoid surgery and has been on ‘watch and wait’ since June 2023.
“I had eight sessions of chemo, followed three weeks later by 28 sessions of radiation with capecitabine. Intravenous chemo was tolerable for me. Radiation was brutal for the last two-and-a-half weeks and for two weeks after. I had persistent burning bowel movements, despite diet adjustments and creams.
“I have a wonderfully supportive family, husband and siblings, that helped me get through treatment. I am extremely grateful for this non-operative pathway because of how common lower anterior resection syndrome is after reconnection from low tumours. I would have to change careers if I had urgency or incontinence. I'm especially happy with my surgeon at Kaiser Roseville for his knowledge of ‘watch and wait’, his close surveillance, and his excellent communication.”
END
Long-course radiotherapy is better than short-course for organ preservation in rectal cancer
But both treatments have similar survival rates
2024-09-11
ELSE PRESS RELEASES FROM THIS DATE:
Large-scale population analysis confirms reassuring safety profile of tirzepatide
2024-09-11
As more people with type 2 diabetes (T2D) are taking medications to help manage blood sugar levels and weight loss, concerns about whether these drugs are safe have emerged. Now real-world evidence from the FDA Adverse Event Reporting System (FAERS) database reveals a reassuring safety profile for tirzepatide (TZP).
The findings to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept), and published in the The Journal of Endocrinological Investigation (link below) reveal that, compared to the widely used class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), TZP has similar gastrointestinal ...
Tirzepatide associated with greater weight loss in women than men
2024-09-11
All doses of tirzepatide, a medication approved in the EU to treat type 2 diabetes and obesity, consistently reduced body weight in women and men, but women experienced greater weight loss, according to new post hoc research to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).
The post hoc analysis, which included the four SURMOUNT trials [1], compared tirzepatide with a placebo for up to 72 to 88 weeks in 4,677 adults (2,999 females, 1,678 males) living with obesity, highlighting potential sex differences in the response.
Tirzepatide, a once-weekly glucose-dependent ...
Rapid control of blood sugar levels in women with gestational diabetes can reverse the risk of their children developing obesity, US study finds
2024-09-11
Swiftly achieving glycaemic control after a diagnosis of gestational diabetes can bring the baby’s risk obesity in childhood down to a level similar to that of children whose mothers did not have gestational diabetes, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), has found.
Gestational diabetes, a type of diabetes that can develop during pregnancy, affects 14% of pregnant women globally and is becoming more common, with those who are living with obesity, have a family ...
Semaglutide’s cardiovascular benefits are maintained in people with impaired kidney function
2024-09-11
The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who don’t have diabetes, whether or not they also have impaired kidney function, according to new research to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).
The results are based on a pre-specified analysis of the SELECT trial which found that adults with overweight or obesity but not diabetes taking semaglutide for more than 3 years had a 20% lower risk of MACE or ...
Study reveals key predictors for achieving and sustaining blood glucose control and weight loss with tirzepatide in adults with type 2 diabetes
2024-09-11
The phase 3 SURPASS-4 trial published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better than insulin glargine (a long-acting insulin) for type 2 diabetes (T2D) [1]. Now new research examining a broad range of potential predictors of sustaining blood sugar control and weight loss indicates that greater weight loss, better β-cell function, and a greater decrease in low-density lipoprotein cholesterol (LDL-C or “bad cholesterol”) during the first year of tirzepatide therapy are the most ...
Avian flu found in wastewater of 10 Texas cities through virome sequencing by researchers at UTHealth Houston and Baylor College of Medicine
2024-09-11
Avian influenza A(H5N1) virus, which spread to cattle and infected 14 people this year, was detected using virome sequencing in the wastewater of 10 Texas cities by researchers at UTHealth Houston and Baylor College of Medicine. The virome is the collection of viruses in a sample, in this case a wastewater sample.
The information was published in the New England Journal of Medicine.
Until March 2024, H5N1 had not been detected in 1,337 wastewater samples analyzed by the team. But from March 4 to July 15 (the end of data collection for this article), H5N1 was ...
Culturing muscle cells
2024-09-11
Harvard stem cell biologists have pioneered a groundbreaking 3D organoid culture method for generating large numbers of adult skeletal muscle satellite cells, also known as muscle stem cells, in vitro.
The ability to efficiently make functional muscle stem cells in this way is expected to accelerate understanding of and treatments for disorders of skeletal muscle, including those that are neuromuscular in origin. The new technique, detailed in Nature Biotechnology, also provides a powerful tool for studying muscle biology.
"People will be able to do all these engraftment and regeneration experiments because suddenly, you have millions of cells,” said co-author and Harvard research ...
ORNL debuts convergent manufacturing platform at IMTS 2024
2024-09-11
A new convergent manufacturing platform, developed in only five months at the Department of Energy’s Oak Ridge National Laboratory, is debuting at the International Manufacturing Technology Show, or IMTS, in Chicago, Sept. 9–12, 2024.
The technology, called Future Foundries, opens the door for hundreds of thousands of small- and medium-sized companies to join the convergent manufacturing revolution, according to ORNL researchers. It is a cutting-edge platform that integrates multiple advanced manufacturing systems into a single, agile platform.
“The democratization ...
New insights could help prevent psychosis relapses in youth and young adults
2024-09-11
New findings from McGill University researchers could help clinicians understand the course of delusions in youth and young adults that signal the need for a timely intervention to prevent a full relapse of psychosis.
Delusions — strong beliefs that don't align with commonly accepted reality— are a defining symptom of psychosis but are not sufficiently understood.
For the first time, researchers studied whether delusion themes, such as paranoia or grandiosity, stay the same or shift between psychotic episodes in youth and young adults undergoing early intervention treatment.
The importance of timely ...
Biogeochemistry scientists from around the world, led by the ASC's Margenot, publish position paper on tackling “hidden” phosphorus
2024-09-11
As the world tries to mitigate agriculture’s effect on the environment, much of the story can be found in the soils, which stores and cycles nutrient elements of carbon, nitrogen, and phosphorus. Biogeochemistssuch as Andrew Margenot, Associate Director of the Agroecosystem Sustainability Center, are set to find answers, but for Margenot and other biogeochemistry experts who specialize in studying phosphorus cycling, the challenge is first being able to accurately measure where phosphorus has accumulated in the <100 years since humans began to increase ...
LAST 30 PRESS RELEASES:
Workforce diversity is key to advancing One Health
Genome Research publishes a special issue on innovations in computational biology
A quick and easy way to produce anode materials for sodium-ion batteries using microwaves
‘Inside-out’ galaxy growth observed in the early universe
Protein blocking bone development could hold clues for future osteoporosis treatment
A new method makes high-resolution imaging more accessible
Tiny magnetic discs offer remote brain stimulation without transgenes
Illuminating quantum magnets: Light unveils magnetic domains
Different types of teenage friendships critical to wellbeing as we age, scientists find
Hawaii distillery project wins funding from Scottish brewing and distilling award
Trinity researchers find ‘natural killer’ cells that live in the lung are ready for a sugar rush
$7 Million from ARPA-H to tackle lung infections through innovative probiotic treatment
Breakdancers may risk ‘headspin hole’ caused by repetitive headspins, doctors warn
Don’t rely on AI chatbots for accurate, safe drug information, patients warned
Nearly $10M investment will expand and enhance stroke care in Minnesota, South Dakota
Former Georgia, Miami coach Mark Richt named 2025 Paul “Bear” Bryant Heart of a Champion
$8.1M grant will allow researchers to study the role of skeletal stem cells in craniofacial bone diseases and deformities
Northwestern to promote toddler mental health with $11.7 million NIMH grant
A new study finds that even positive third-party ratings can have negative effects
Optimizing inhibitors that fight antibiotic resistance
New Lancet Commission calls for urgent action on self-harm across the world
American Meteorological Society launches free content for weather enthusiasts with “Weather Band”
Disrupting Asxl1 gene prevents T-cell exhaustion, improving immunotherapy
How your skin tone could affect your meds
NEC Society, Cincinnati Children's, and UNC Children’s announce NEC Symposium in Chicago
Extreme heat may substantially raise mortality risk for people experiencing homelessness
UTA professor earns NSF grants to study human-computer interaction
How playing songs to Darwin’s finches helped UMass Amherst biologists confirm link between environment and the emergence of new species
A holy grail found for catalytic alkane activation
Galápagos finches could be singing a different song after repeated drought—one that leads to speciation
[Press-News.org] Long-course radiotherapy is better than short-course for organ preservation in rectal cancerBut both treatments have similar survival rates